JNJ - Johnson & Johnson
132.39 +0.32 (0.24%)
Pre-market: 4:23AM EDT
| Previous close | 131.86 |
| Open | 0.00 |
| Bid | 132.23 x 800 |
| Ask | 132.55 x 800 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | 0 |
| Avg. volume | 7,043,685 |
| Market cap | 350.654B |
| Beta (3Y monthly) | 0.76 |
| PE ratio (TTM) | 21.93 |
| EPS (TTM) | 6.02 |
| Earnings date | 15 Oct 2019 |
| Forward dividend & yield | 3.80 (2.88%) |
| Ex-dividend date | 2019-08-26 |
| 1y target est | 149.28 |
- Zacks•13 hours ago
3 Key Takeaways From J&J's (JNJ) Q2 Earnings Announcement
Here are some of the highlights of J&J's (JNJ) second-quarter earnings call.
- Zacks•16 hours ago
Top Stock Reports for Johnson & Johnson, NextEra & Deere
Top Stock Reports for Johnson & Johnson, NextEra & Deere
- Market Realist•19 hours ago
Litigation Looms in the Wake of JNJ’s Solid Q2 Earnings
Johnson & Johnson (JNJ) reported its second-quarter earnings results before the market opened on Tuesday.
- Motley Fool•20 hours ago
5 Signs of Life in Johnson & Johnson's Second-Quarter Earnings Report
Investors worried about dwindling sales of key drugs and mounting litigation expenses have at least five reasons to stay calm.
- Zacks•2 days ago
Healthcare ETFs in Focus on JNJ's Q2 Earnings Beat
Johnson & Johnson beat the second-quarter earnings and revenue estimates but warned on competition from generics and biosimilars that could impact its third-quarter results.
- Yahoo Finance•3 days ago
Johnson & Johnson CFO on the opioid crisis: 'We don’t believe we were the cause'
Pharmaceutical companies are facing increasing scrutiny for their alleged roles in the opioid crisis. Its next target? Johnson & Johnson (JNJ).
- Yahoo Finance•3 days ago
Stocks slip slightly amid trade remarks, earnings season
U.S. stocks were mixed Tuesday afternoon as investors digested a wave of signals from officials over U.S.-China trade relations and monetary policy, along with an influx of corporate earnings results and economic data.
Motley Fool•3 days agoJohnson & Johnson (JNJ) Q2 2019 Earnings Call Transcript
JNJ earnings call for the period ending June 30, 2019.
- Bloomberg•3 days ago
J&J Ups Sales Forecast as Cancer Drugs Drive Growth
(Bloomberg) -- Johnson & Johnson raised its revenue guidance for the year, as strong sales in its pharmaceutical unit helped cushion a decline in the consumer and medical technology businesses.Second-quarter adjusted earnings were $2.58 a share, topping the $2.45 average of analysts’ estimates. To read more details on the results, click here.Key InsightsThe company’s full revenue is actually down from a year prior. Part of that can be attributed to the company’s divestiture of its medical sterilization business, ASP, which it sold to Fortive Corp. earlier this year. The company was also hit badly by foreign exchange rates. Almost half of J&J’s sales come from outside the U.S., and its fastest-growing segment -- overseas pharmaceuticals -- had its growth cut nearly in half because of currency fluctuations.J&J’s drug business is the largest of the company’s three main segments and accounts for more than half of all revenue. Its cancer drugs, including Darzalex and Imbruvica, drove growth in the quarter and were up 9.8% from a year prior.Market ReactionThe shares were down 1% to $133.41 at 9:43 a.m. in New York. The stock is up 4.4% this year to date as of Monday’s close, trailing the broader market.(Corrects spelling of cancer drug Darzalex in “Key Insights” section.)To contact the reporter on this story: Riley Griffin in New York at rgriffin42@bloomberg.netTo contact the editor responsible for this story: Drew Armstrong at darmstrong17@bloomberg.netFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
- CNBC•3 days ago
J&J vows to defend itself in talc, opioid lawsuits
Johnson & Johnson vowed to defend itself against lawsuits alleging the company fueled the opioid crisis and that its namesake talc-based baby powder caused ovarian cancer and mesothelioma.
- Zacks•3 days ago
AbbVie (ABBV) Acquires Mavupharma to Boost Cancer Portfolio
AbbVie (ABBV) buys Mavupharma to develop novel treatments for cancer using the latter's STING signaling pathway.
- Zacks•3 days ago
J&J (JNJ) Beats on Q2 Earnings, Ups 2019 Sales Growth View
J&J (JNJ) beats estimates for both earnings and sales in the second quarter of 2019 and raises 2019 guidance for operational sales growth for the second time this year.
- Zacks•3 days ago
Retail Sales Up, Import Prices Down, Q2 Earnings Solid
Retail Sales outperformed, Imports & Exports were lower, and JPM, WFC, GS and JNJ outperformed earnings expectations.
- MarketWatch•3 days ago
Goldman's stock rally helps keep Dow positive
Shares of Goldman Sachs Group Inc. surged 2.3% in morning trading after big second-quarter profit and revenue beats, with the price gain enough to keep the Dow Jones Industrial Average in positive territory. The stock rose $4.88, which would add about 33 points to the Dow's price, which is up 7 points. For the other Dow earnings reporters, J.P. Morgan Chase & Co.'s stock slipped 41 cents, or 0.4%, and Johnson & Johnson shares gave up $1.60, or 1.2%; combined, those declines would shave about 14 points off the Dow's price.
- MarketWatch•3 days ago
Stocks pull back from record levels as earnings season picks up steam
Stocks got off to a slightly lower start Tuesday as investors digested a stream of earnings reports, including results from Dow components Johnson & Johnson and Goldman Sachs Group Inc. . The Dow Jones Industrial Average fell around 7 points, or less than 0.1%, to 27,352, while the S&P 500 was off 0.1% at 3,011.12. The Nasdaq Composite fell 0.1% to 8,245.28. All three major indexes eked out record finished in subdued trading on Monday. Shares of Goldman Sachs were up 0.9%, while Johnson & Johnson shares fell 1.7%. Both companies topped earnings forecasts.
- Investing.com•3 days ago
Stocks - JP Morgan, Wells Fargo Fall Premarket; J&J, Goldman Sachs Rise
Investing.com - Stocks in focus in premarket trading on Tuesday:
- Zacks•3 days ago
Johnson & Johnson (JNJ) Tops Q2 Earnings and Revenue Estimates
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 6.61% and 1.17%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Reuters•3 days ago
J&J warns of hit from generic drugs in third quarter, shares fall
While J&J's pharmaceuticals unit has in recent years cushioned the impact of relatively slow growth in the company's medical device and consumer units, some of its older drugs have been hurt by competition from cheaper copies. "We expect the largest impacts from generics and biosimilars for the year in our pharmaceutical business to occur in the third quarter," Chief Financial Officer Joseph Wolk said on a conference call. Sales of prostate cancer treatment Zytiga fell 23% in the quarter, hurt by generic copies, and sales of J&J's blockbuster arthritis drug Remicade fell 16%, impacted by biosimilar rivals.
- CNBC•3 days ago
Stocks making the biggest moves premarket: Goldman Sachs, JP Morgan, J&J, KeyCorp & more
These are the stocks posting the largest moves before the bell.
- Investing.com•3 days ago
Johnson & Johnson Lifts Sales Guidance After Q2 Earnings Beat
Investing.com - Johnson & Johnson (NYSE:JNJ) lifted its annual sales outlook for the year after reporting second-quarter earnings that beat consensus on the top and bottom line.
- CNBC•3 days ago
What to watch today: Bank earnings, tech hearings on Capitol Hill, and alleged Tesla shortcuts
U.S. stock futures point to a mixed open after a day of small gains kept the record closes going on Wall Street.
- MarketWatch•3 days ago
Shares of J&J up 0.8% after earnings and revenue beat
Shares of Johnson & Johnson rose 0.8% in premarket trade Tuesday after the health-products giant reported second-quarter earnings and revenue that beat Wall Street expectations. Profit for the latest quarter rose to $5.607 billion, or $2.08 per share, from $3.954 billion, or $1.45 per share, a year ago. Adjusted EPS was $2.58 per share, beating the FactSet consensus of $2.46 per share. Revenue fell to $20.562 billion from $20.830 billion in the year-earlier quarter, but beat the FactSet consensus of $20.293 billion. Sales from J&J's consumer business rose to $3.544 billion from $3.504 billion a year ago, while the company's pharmaceuticals segment brought in $10.529 billion, up from $10.354 billion a year ago. J&J's medical devices business brought in $6.489 billion, down from $6.972 billion a year ago. J&J boosted its 2019 sales outlook to between $80.8 billion and $81.6 billion from between $80.4 billion and $81.2 billion. The company also reaffirmed its full-year adjusted EPS of between $8.53 and $8.63 per share. Shares of J&J have gained 4.4% in the year to date, while the Dow Jones Industrial Average has gained 17.3% and the S&P 500 has gained 20.2%.
